1. Academic Validation
  2. The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis

The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis

  • Mol Cell. 2012 Dec 28;48(6):900-13. doi: 10.1016/j.molcel.2012.09.030.
John E Dominy Jr 1 Yoonjin Lee Mark P Jedrychowski Helen Chim Michael J Jurczak Joao Paulo Camporez Hai-Bin Ruan Jessica Feldman Kerry Pierce Raul Mostoslavsky John M Denu Clary B Clish Xiaoyong Yang Gerald I Shulman Steven P Gygi Pere Puigserver
Affiliations

Affiliation

  • 1 Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Abstract

Hepatic glucose production (HGP) maintains blood glucose levels during fasting but can also exacerbate diabetic hyperglycemia. HGP is dynamically controlled by a signaling/transcriptional network that regulates the expression/activity of gluconeogenic enzymes. A key mediator of gluconeogenic gene transcription is PGC-1α. PGC-1α's activation of gluconeogenic gene expression is dependent upon its acetylation state, which is controlled by the acetyltransferase GCN5 and the deacetylase SIRT1. Nevertheless, whether other chromatin modifiers-particularly other sirtuins-can modulate PGC-1α acetylation is currently unknown. Herein, we report that SIRT6 strongly controls PGC-1α acetylation. Surprisingly, SIRT6 induces PGC-1α acetylation and suppresses HGP. SIRT6 depletion decreases PGC-1α acetylation and promotes HGP. These acetylation effects are GCN5 dependent: SIRT6 interacts with and modifies GCN5, enhancing GCN5's activity. Lepr(db/db) mice, an obese/diabetic animal model, exhibit reduced SIRT6 levels; ectopic re-expression suppresses gluconeogenic genes and normalizes glycemia. Activation of hepatic SIRT6 may therefore be therapeutically useful for treating insulin-resistant diabetes.

Figures